拉丁美洲林奇综合征筛查策略的特征分析
研究分析了拉丁美洲24个遗传性癌症登记中心1999至2020年间1684例结直肠癌患者的临床与分子数据,评估林奇综合征筛查策略的实施情况。72%的病例有可用的筛查策略,其中78%采用通用肿瘤筛查,22%采用传统筛查。通用肿瘤筛查确认林奇综合征的比例为53.3%,传统筛查为47.8%,差异无统计学意义(P=0.175)。
要点
- 拉丁美洲林奇综合征筛查中78%采用通用肿瘤筛查,22%采用传统筛查。
- 通用肿瘤筛查发现错配修复缺陷肿瘤的比例为29%。
- 通用肿瘤筛查确认林奇综合征的比例53.3% vs 传统筛查47.8%,差异无统计学意义(P=0.175)。
核心结论
- 通用肿瘤筛查在拉丁美洲广泛实施,但本研究显示的林奇综合征低检出率令人担忧该地区常规使用胚系基因检测的做法。
- 研究提供了真实世界结果,揭示筛查接受和咨询转诊方面的差异,说明拉丁美洲国家在遗传性癌症综合征筛查中面临的挑战。
- 这些结果有助于为设计有效的林奇综合征筛查策略提供依据,最终可能也适用于其他遗传性癌症综合征。
研究设计与样本
- 由24个拉丁美洲遗传性癌症登记中心和中心提供1999年至2020年间收集的1684例结直肠癌患者的临床和分子数据。
- 并非所有病例均一致进行胚系基因检测。
主要发现
- 72%(1209/1684)的病例有可用的林奇综合征筛查策略,其中四分之一(304/1209)进行了胚系检测。
- 多数病例(78%;n=943)接受通用肿瘤筛查,主要在阿根廷、智利和乌拉圭;22%(266/1209)通过传统筛查进行筛查。
- 通用肿瘤筛查在29%(272/943)的病例中识别出错配修复缺陷肿瘤。
- 通过测序确认林奇综合征的比例,通用肿瘤筛查为53.3%(65/122),传统筛查为47.8%(87/182),差异无统计学意义(P=0.175)。
关键数值与推荐
- 传统筛查可能漏诊高达68%的林奇综合征病例。
- 通用肿瘤筛查涉及对所有新诊断结直肠癌患者进行分子标志物筛查,以更有效识别林奇综合征病例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 并非所有病例均一致进行胚系基因检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In Latin America, genetic testing for Lynch syndrome (LS) has been partially implemented. Traditionally, LS diagnosis relied on the Amsterdam criteria and Bethesda guidelines, collectively known as traditional screening (TS). However, TS may miss up to 68% of LS cases. To improve detection rates, universal tumor screening (UTS) has been introduced. UTS involves screening all newly diagnosed patients with colorectal cancer for molecular markers to more effectively identify LS cases. METHODS: Clinical and molecular data on 1684 patients with colorectal cancer, collected between 1999 and 2020, were provided by 24 Latin American genetic cancer registries and centers. Germline genetic testing was not consistently performed across all cases. RESULTS: LS screening strategies were available for 72% (1209/1684) of cases, with germline testing conducted in one-quarter (304/1209) of these. Most cases (78%; n = 943) underwent UTS, primarily in Argentina, Chile, and Uruguay, whereas 22% (266/1209) were screened through TS. UTS identified deficient mismatch repair tumors in 29% (272/943) of cases. The rate of LS confirmed by sequencing was higher with UTS (53.3%; 65/122) compared with TS (47.8%; 87/182), although the difference was not statistically significant (P = .175). CONCLUSIONS: UTS is widely implemented in Latin America; however, the low detection rate of LS demonstrated in this study raises concerns about the routine use of germline genetic testing in our region. Our study provides real-world outcomes that highlight disparities in screening uptake and counseling referrals, illustrating the challenges that Latin American countries face in hereditary cancer syndrome screening. These results contribute to the rationale for designing effective screening strategies for LS, which may also be applicable to other hereditary cancer syndromes, ultimately.
引用
- Campos-Segura AV, Alvarez K, Murillo Carrasco AG, et al. Characterization of Screening Strategies for Lynch Syndrome in Latin America. Clin Gastroenterol Hepatol. 2025. PMID: 40010418. doi:10.1016/j.cgh.2024.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。